Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term cisplatin. Found 96 abstracts

no pagination
Abbosh PH, Plimack ER. Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer. Bladder cancer (Amsterdam, Netherlands). 2018 Jan 20;4(1):9-18.   PMCID: PMC5798524
Arora S, Heyza JR, Chalfin EC, Ruch RJ, Patrick SM. Gap Junction Intercellular Communication Positively Regulates Cisplatin Toxicity by Inducing DNA Damage through Bystander Signaling. Cancers. 2018 Oct 02;10(10).   PMCID: PMC6210410
Heyza JR, Arora S, Zhang H, Conner KL, Lei W, Floyd AM, Deshmukh RR, Sarver J, Trabbic CJ, Erhardt P, Chan TH, Dou QP, Patrick SM. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells. Nutrients. 2018 Nov;10(11).   PMCID: PMC6267282
Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J, Yu EY, Niegisch G, Vaishampayan UN, Theodore C, Berthold DR, Srinivas S, Sridhar SS, Plimack ER, Rosenberg JE, Powles T, Galsky MD, Necchi A. Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. J Urol. 2018 Dec;200(6):1207-14.
Li PD, Liu Z, Cheng TT, Luo WG, Yao J, Chen J, Zou ZW, Chen LL, Ma C, Dai XF. Redox-dependent modulation of metformin contributes to enhanced sensitivity of esophageal squamous cell carcinoma to cisplatin. Oncotarget. 2017 Sep 22;8(37):62057-68.   PMCID: PMC5617486
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract I. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug;121(15):2586-93.
Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. 2014 Apr;12(2):130-7.   PMCID: Pmc4142680
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 2012 Dec;127(3):538-43.   PMCID: PMC3568489
Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, Carpeno JD, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. British Journal of Cancer. 2012 Oct;107(8):1277-85.   PMCID: PMC3494447
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB. Testicular Cancer Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2012 Apr;10(4):502-35.   PMCID: not NIH funded
Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. A Phase 2 Trial of Bortezomib Followed by the Addition of Doxorubicin at Progression in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck A Trial of the Eastern Cooperative Oncology Group (E1303). Cancer. 2011 Aug;117(15):3374-82.   PMCID: PMC3135694
Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ. A phase II, single-arm study of the anti-alpha 5 beta 1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecologic Oncology. 2011 May;121(2):273-9.   PMCID: not NIH funded
Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, Huang M, Chernoff J, Boorjian SA. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU international. 2011 Jul;108(2B):E84-E90.   PMCID: PMC3116980
Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G, Nccn Gastric Canc Panel Members. Gastric Cancer Clinical Practice Guidelines in Oncology (TM). Journal of the National Comprehensive Cancer Network. 2010 Apr;8(4):378-409.   PMCID: not NIH funded
Randall LM, Monk BJ, Moon J, Parker R, Al-Ghazi M, Wilczynski S, Fruehauf JP, Markman M, Burger RA. Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: A Southwest Oncology Group Study. Gynecologic Oncology. 2010 Dec;119(3):417-21.   PMCID: PMCID: PMC2978536 [Available on 2011/12/1]
Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen CH. INITIAL RESULTS OF A PHASE I DOSE-ESCALATION TRIAL OF CONCURRENT AND MAINTENANCE ERLOTINIB AND REIRRADIATION FOR RECURRENT AND NEW PRIMARY HEAD-AND-NECK CANCER. International Journal of Radiation Oncology Biology Physics. 2010 Nov;78(4):1020-5.   PMCID: not NIH funded
Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansar R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 2006 May;24(13):2038-43.
Ozols RF. Management of ovarian cancer - An impressive history of improvement in survival and quality of life - The Markman article reviewed. ONCOLOGY-NEW YORK. 2006 Apr;20(4):354-+.
Ozols RF, Bookman MA, Young RC. Intraperitoneal chemotherapy for ovarian cancer. New England Journal of Medicine. 2006 Apr;354(15):1641-2.
Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, Johnson DH, Eastern Cooperative Oncology Grp. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. JOURNAL OF THORACIC ONCOLOGY. 2006 Jun;1(5):441-6.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term cisplatin

cisplatin chemotherapy doxorubicin paclitaxel therapy expression carcinoma chemoresistance bladder cancer endothelial growth-factor gemcitabine positron-emission-tomography NCCN Clinical Practice Guidelines Oncology lymph-node dissection regimen bevacizumab mortality trial radiotherapy multiple-myeloma therapeutic use prediction administration & dosage Multicenter Studies as Topic Ercc1-xpf 1st-line therapy 1980 nnock if-v46-p452 nonseminoma cisplatin-based chemotherapy metastatic colorectal-cancer malignant gastroduodenal obstruction prognostic indicators testicular cancer cells gap junction intercellular communication germ-cell tumors plus cisplatin chemotherapeutic-agents therapeutic strategy squamous-cell carcinoma indiana-university experience analogs & derivatives mutations Ercc1 Overall survival gap junction liposomal Endometrial cancer Aflibercept-VEGF Trap-Toxicity-Fibroblast growth factor multicenter phase-ii concurrent chemotherapy pancreatic-cancer raf kinase combination breast-cancer Male human lactate dehydrogenase Neoadjuvant Therapy ii trial Female bladder-cancer salivary-gland carcinomas pelvic irradiation alpha(5)beta(1) integrin cancer kappa-b-alpha plus cetuximab dna-damage DNA damage response immunotherapy muscle invasion radical cystectomy 2010 ung pw-j clin oncol-v28 vincristine phase-iii trial susceptibility salvage chemotherapy Platinum resistant s-1 plus cyclophosphamide platinum-containing gastroesophageal NCCN Guidelines carboplatin oncology-group Progression-free survival at 6 months 2011 ung p-j natl cancer i-v103-p194 repair Adult Volociximab seminoma smoking rapamycin connexin 43 Middle Aged Ovarian cancer vegf high-dose surgery head and neck cancer 80 and over Aged Cisplatin estrogen junction adenocarcinoma 2002 ung p-can j urol-v9-p1637 hydroxyurea Transitional Cell Carcinoma In vitro assay Reirradiation Second-line treatment pathology upper gastrointestinal inhibitor circulating tumor-cells proteasome inhibitor ps-341 mammalian target vinflunine gender alpha 5 beta 1 integrin mouse model urinary tract stage-i seminoma growth-factor General & Internal Medicine transitional-cell carcinoma Muscle Neoplasms chemoresponse in-vitro gemcitabine plus cisplatin angiogenesis Chemoradiation chorionic gonadotropin green tea polyphenols Treatment Outcome resection (JNCCN 8:378-409) Cervical cancer gefitinib survival cell-death cooperative-oncology-group adenoid cystic carcinoma Urinary Bladder Neoplasms statistics & numerical data xpf Retrospective Studies 1993 bruin mjfm-british journal of urology-v71-p336 Methotrexate neoadjuvant
Last updated on Monday, July 06, 2020